When Missing a Signal Is Catastrophic: Product Management for Pharmacovigilance

Pharmacovigilance product management means building intake, triage, and signal-detection systems that treat a missed adverse-event signal as catastrophically expensive and a false alarm as merely annoying — the inverse of how most consumer products get tuned. That means optimizing thresholds, eval criteria, and workflows for recall over precision, then engineering regulatory-timeline compliance and full auditability around that asymmetry from the first sprint.

Quick answer: In pharmacovigilance, recall matters more than precision because a missed adverse-event signal (a false negative) can delay a label change, a market action, or care that would have prevented real harm — while a false alarm (a false positive) only costs a reviewer's time. Design your case-intake pipeline, your eval criteria, and your audit trail around that asymmetry, not around a balanced accuracy score.

Why Pharmacovigilance Product Management Runs on Recall, Not Precision

Most product teams tune a classifier, a triage queue, or a ranking model to balance precision and recall, because a false positive and a false negative cost the business roughly the same amount of trust. Pharmacovigilance breaks that symmetry on purpose: a missed adverse-event signal can delay a label change, a risk communication, or a withdrawal that would have prevented real patient harm, while a false alarm mostly costs a safety reviewer an extra ten minutes.

Picture the moment this gets real. A case-intake model flags an incoming report as a "likely duplicate" of one filed last month and auto-closes it to keep the queue moving. Three weeks later, a routine disproportionality run surfaces the same adverse-event pattern from six other markets — except your case never made it into the dataset, because it was closed before anyone with medical judgment looked at it. Nobody did anything wrong on paper. The workflow just optimized for the wrong thing.

A false positive costs a reviewer ten minutes. A false negative can cost a delayed label change, a regulatory finding, or a preventable second injury — the same field on a dashboard, two entirely different bills.

The standard product playbook fails here for a specific reason: it assumes you can pick a single operating point on a precision-recall curve and defend it with an F1 score or a balanced-accuracy target. That assumption holds when the two error types are financially and reputationally interchangeable. It collapses the moment one error type — a missed signal — is regulated, litigable, and potentially fatal, while the other — a false alarm — is merely expensive to triage.

The mental-model shift a PM has to make is this: recall is the primary objective, and precision is a resourcing constraint on top of it, not a co-equal metric. You don't ask "what threshold maximizes F1?" You ask "what's the maximum false-positive volume my safety team can review without missing something in the backlog, and what recall can I sustain within that constraint?"

That reframing changes every downstream decision — thresholds, eval weighting, staffing, and how you report health metrics upward. For the wider regulatory and organizational context this decision sits inside, our complete guide to biotech and pharma product management covers the adjacent terrain most pharmacovigilance products also have to navigate.

The Case-Intake-to-Signal-Detection Pipeline: What You're Actually Building

A pharmacovigilance product spans five connected stages — case intake, triage and deduplication, case processing and coding, signal detection and validation, and safety governance review — and each stage has a different owner, a different regulatory clock, and a different way it can fail. Understanding the pipeline as one system, not five separate features, is the difference between building a product and building a set of disconnected screens.

Two things make this pipeline unusual compared to most product funnels. First, the input is already lossy before your product touches it — a widely cited review by Hazell and Shakir, published in the journal Drug Safety, found underreporting rates in spontaneous adverse-event reporting systems commonly running well above 90% across the studies it examined. Your intake screen isn't just a form; it's competing against a structural tendency for real events to never surface at all.

Second, the pipeline is a feedback loop, not a straight line: weak intake produces a weak signal, a weak signal delays action, delayed action means continued exposure, and continued exposure produces more of the same adverse events. That's a reinforcing loop a causal-loop diagram makes visible in a way a linear funnel chart never will.

Our complete guide to systems thinking walks through exactly this kind of loop-mapping, worth doing before you design triage logic, because it shows where a small delay compounds into a much larger downstream gap. Mapping the reporter's actual experience — the patient or clinician deciding whether a report is even worth the friction of filing — the way a customer journey emotion curve maps moments of friction and drop-off, routinely finds more leverage than optimizing the internal triage screen ever does.

Regulatory Reporting Timelines: Designing to the Clock, Not Just the Signal

Pharmacovigilance products don't get to treat "when we report" as a business decision — expedited reporting windows are set in regulation, measured in calendar days from the moment anyone in your organization becomes aware of a case, and missing one is a compliance finding independent of whether the underlying signal was real. A PM has to design the pipeline's throughput around the clock, not just around detection accuracy.

The clock starts at Day Zero: the moment any employee, contractor, or affiliate first becomes aware of a reportable event, not the moment it's fully processed. That single definition drives most of the internal SLA pressure a pharmacovigilance product exists to manage.

Three design implications fall out of this table directly:

1. Your triage SLA has to leave enough runway for medical review before the regulatory deadline, not right up against it — a case that clears triage on day 14 of a 15-day window leaves zero margin for a causality dispute.
2. "Serious and unexpected" is a determination, not a field a reporter fills in — your product needs a workflow for a trained reviewer to make and document that call, because it's what starts the expedited clock in the first place.
3. Periodic reports run on a completely different cadence than case reports, which means your product needs two separate SLA dashboards, not one blended "reporting health" metric that hides which clock is actually at risk.

Where AI/NLP Triage Earns Its Keep — and Where a Human Has to Stay in the Loop

AI and NLP genuinely help with the mechanical front end of the pipeline — deduplication, literature screening, draft MedDRA coding suggestions, and narrative-drafting assistance — but causality assessment, seriousness determination, and any decision that becomes the basis for a regulatory submission need a licensed reviewer's judgment and signature, not a model's confidence score. The line isn't "AI versus human," it's "which decisions are mechanical pattern-matching and which are medical-legal judgment calls."

Statistical disproportionality analysis — methods like the Proportional Reporting Ratio (PRR), the Reporting Odds Ratio (ROR), and the Multi-item Gamma Poisson Shrinker (MGPS, which drives the Empirical Bayes Geometric Mean or EBGM scores used inside FDA's FAERS signal-detection tooling) — is decades-old statistics, not new AI, and it already does a version of recall-first design: it's tuned to surface candidate signals liberally and let human reviewers filter them, not to quietly suppress weak ones.

The job a drug safety physician is actually hired to do isn't "process cases faster" — it's "make a causality call I can defend to an inspector two years from now." Thinking about that distinction through a Jobs-to-be-Done lens is useful precisely because it separates the functional job (get through the queue) from the outcome the reviewer is really accountable for (a defensible medical judgment), and no NLP triage model — however good its suggestions — can satisfy the second one on its own.

A triage model that's 95% accurate at suggesting a MedDRA code is still 100% wrong the one time it silently miscodes the case that would have completed a signal — and nobody reviews a suggestion they never see flagged as uncertain.

Building Auditability In: What an Inspector Will Actually Ask to See

An inspector doesn't ask whether your signal-detection model was accurate — they ask whether you can reconstruct, case by case, who saw what, when, what they decided, and why, from the moment a report arrived to the moment it was submitted or closed. Auditability isn't a reporting feature bolted on afterward; it's a structural requirement on the data model itself.

At minimum, a defensible pharmacovigilance system needs:

• An immutable case history — every triage decision, coding change, and seriousness determination recorded as an append-only entry with an actor, a timestamp, and a reason, never overwritten in place.
• Traceability from raw intake to submitted report — a reviewer should be able to start at a submitted ICH E2B(R3) case and trace backward to the original source document without a manual reconstruction project.
• A documented rationale for every AI/NLP-assisted decision a human accepted or overrode — if a coder accepted an auto-suggested MedDRA term, that acceptance is itself part of the audit trail, not just the final code.
• Retention that survives system migrations — pharmacovigilance records commonly need to remain retrievable for a decade or more, well past the lifespan of the tool that created them.

This is the same discipline our piece on data integrity as a product requirement in life sciences walks through under the ALCOA+ framework — attributable, contemporaneous, and original records aren't unique to lab data. A case narrative that's silently editable in place fails the same audit test a manufacturing batch record would.

Most pharmacovigilance systems also touch electronic signatures and records governed by 21 CFR Part 11, so our computer system validation and Part 11 playbook is worth reading alongside this one. The traceability matrix it describes is the same artifact an inspector will expect to see behind your case-processing workflow, not a separate document.

Framing the Precision/Recall Tradeoff to a Safety Board

A safety board doesn't want a single accuracy number — it wants to see, in plain terms, what a missed signal costs versus what an extra reviewer-hour costs, and it wants that tradeoff presented as a policy decision the board is making, not a threshold a model quietly picked. The framing move is to replace "our model is 92% accurate" with a cost-asymmetry table the board can actually deliberate over.

Build the conversation around a simple four-cell breakdown, described in consequence terms rather than statistics:

Once the board sees the bottom-right cell in plain language, the conversation shifts from "how accurate is the model" to "how much reviewer capacity are we willing to fund to keep recall high" — which is the actual resourcing question a board can approve a budget against.

Three moves make that conversation land instead of stalling in a metrics debate:

1. Present threshold choice as a capacity decision, not a data-science default. Ask the board to approve a maximum sustainable false-positive review load, then back-solve the detection threshold from that number — not the other way around.
2. Report recall separately for high-severity and unexpected cases. A blended recall number can look healthy while quietly hiding a lower recall rate on exactly the rare, severe, unexpected cases where a miss matters most.
3. Show the board what a missed case actually looked like once, using a real (de-identified) near-miss, not a hypothetical — a concrete story about a case that almost fell through triage does more to calibrate risk appetite than another slide of ROC curves.

Building This Weighting Into Your Eval Criteria

This is where Prodinja's evals and UX-of-failure framing transfer directly into a pharmacovigilance context. Prodinja's Evals studio is built to walk you through naming the qualities a feature is graded on, tagging test cases as typical, edge, or adversarial, and setting the percentage that must pass before you'd trust the feature in production — the same "how good is good enough" question a safety board is really asking, just formalized into a rubric.

For a case-triage or signal-detection feature, the design move is to weight your adverse-event test cases so a missed real signal counts as a hard fail regardless of the aggregate pass rate. Don't let it wash out inside a 90%-and-rising number that never says which 10% is failing.

Prodinja's UX-of-failure studio's likelihood-times-severity ranking, and its explicit toggle for a failure that's "silent — nothing looks wrong, it's just quietly incorrect," maps almost exactly onto a missed safety signal: the one failure mode a pharmacovigilance product can least afford, precisely because it never announces itself the way an error message would. That's the intended shape of the prototype experience — a structured way to make the false-negative cost explicit in your own criteria, not a claim that any tool grades your safety data for you.

Key Takeaways

• Recall is the primary objective in pharmacovigilance products, and precision is a resourcing constraint on top of it — not a co-equal metric to balance against a single accuracy score.
• The case-intake-to-signal-detection pipeline is one system with five stages, each with its own failure mode and owner; treating it as five disconnected screens is how signals get lost between them.
• Underreporting is a structural starting condition, not a product defect you can fully engineer away — design intake to compete against it, not assume it away.
• Expedited reporting clocks start at Day Zero — first awareness — not at case completion, so triage SLAs need to leave real margin before the regulatory deadline, not run right up against it.
• AI and NLP genuinely help with deduplication, coding suggestions, and literature screening, but causality assessment, seriousness determination, and submission sign-off require a human reviewer's documented, defensible judgment.
• Auditability has to be structural, not a reporting layer bolted on later — immutable case history, full traceability, and long-horizon retention are data-model decisions, not QA checklist items.
• Frame the precision/recall tradeoff to a safety board as a cost-asymmetry and resourcing decision, not an accuracy score — show what a false negative actually costs before asking the board to approve a threshold.